Abraxane Beats Standard Breast Cancer Treatment
Study Shows Abraxane Works Better Than Standard Chemotherapy for Metastatic Breast Cancer
WebMD News Archive
June 3, 2009 (Orlando, Fla.) -- For women with breast cancer that has spread to other parts of the body, the chemotherapy drug Abraxane works better, and with fewer side effects, than the standard drug treatment, a new study suggests.
Abraxane prolonged the time to cancer progression by nearly seven months, compared with standard Taxotere, says study head William Gradishar, MD, director of breast medical oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University In Chicago.
"The findings support the use of Abraxane as first-line therapy for women with metastatic breast cancer," he tells WebMD.
The study was published in the May 26 issue of the Journal of Clinical Oncology.
At the annual meeting of the American Society of Clinical Oncology (ASCO) here this week, breast cancer specialists like Jennifer K. Litton, MD, of the University of Texas M.D. Anderson Cancer Center in Houston, told WebMD that the data support what they have been doing in their practices.
Abraxane is approved to treat metastatic breast cancer after other treatments have failed, but more and more doctors are using it as a first treatment for breast cancer that has spread, Litton says.
"Abraxane is very well-tolerated, with fewer side effects [than Taxotere]."
Taxotere and Abraxane are both members of a class of drugs known as taxanes. The major difference: Taxotere needs to be dissolved in a chemical solvent to create a liquid that can be injected into the bloodstream, Litton says.
"Many people can have a severe allergic reaction to the chemical solvent that is used with Taxotere. Also, you may have to premedicate patients with steroids, which have their own set of problems such as fluid retention and poor blood sugar control in diabetics," Litton says.
The chemical solvents can also cause a drop in the white blood cell count and numbness or tingling in the fingertips, Gradishar says.
In contrast, Abraxane uses a human protein to create a fatty envelope to deliver the chemotherapy, Litton says, and the use of chemical solvents is avoided.
Abraxane vs. Breast Cancer
The new study involved 302 women with previously untreated advanced metastatic breast cancer.
They women were randomly assigned to one of four treatment groups. Three groups were administered Abraxane, given one of three ways: every three weeks, weekly at a lower dose for three weeks with the fourth week off, or weekly at a higher dose for three weeks with the fourth week off. The fourth group was given Taxotere at the standard dose every three weeks.
Results showed that Abraxane worked best when given weekly, at either dose, with the fourth week off.
Women in all three Abraxane groups suffered less fatigue and were less likely to have dangerous drops in their white blood cell counts than those on Taxotere.